A Randomized Double-blind, Parallel Group Study Comparing Olanzapine (Zyprexa) With Haloperidol (Novo-peridol) for the Relief of Nausea and Vomiting in Patients With Advanced Cancer

Alberta Health services1 site in 1 country80 target enrollmentMay 2005

ConditionsNausea Neoplasms

DrugsOlanzapine Haldol

Overview

Phase: Phase 3
Intervention: Not specified
Conditions: Nausea
Sponsor: Alberta Health services
Enrollment: 80
Locations: 1
Primary Endpoint: Severity of nausea on days 3 and 5
Status: Terminated
Last Updated: 14 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to compare the efficacy and safety of Haldol (haloperidol) and olanzapine in the control of chronic nausea with advanced cancer patients who have failed first line antiemetic therapy.

Detailed Description

The purpose of this study is to compare the efficacy and safety of haloperidol and olanzapine in the control of chronic nausea with advanced cancer patients who have failed first line antiemetic therapy.

Registry

clinicaltrials.gov

Start Date

May 2005

End Date

June 2008

Last Updated

14 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Alberta Health services

Eligibility Criteria

Inclusion Criteria

•\>18 years of age
•Significant nausea/vomiting
•Failed maxeran and domperidone
•Underlying treatment of causes has failed
•Adequate cognitive function
•Communicates well

Exclusion Criteria

•Partial/complete bowel obstruction
•Currently taking Haldol or olanzapine
•Has drug induced extrapyramidal symptoms
•Parkinson's disease
•Undergoing chemotherapy or radiotherapy (RT) to brain, abdomen, stomach or esophagus